<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01129011</url>
  </required_header>
  <id_info>
    <org_study_id>PN400-302</org_study_id>
    <nct_id>NCT01129011</nct_id>
  </id_info>
  <brief_title>Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers Compared to Non-steroidal Antiinflammatory Drug (NSAID) Naproxen</brief_title>
  <official_title>6-Month, Phase 3, Randomized, Double-blind, Parallel-group, Controlled, Multi-center Study Evaluate Gastric Ulcer Incidence Following Administration of PN400 or Naproxen in Subjects Who Are at Risk for Developing NSAID-associated Ulcers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>POZEN</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>POZEN</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study uses a randomized, double-blind, controlled design to demonstrate that PN400
      (esomeprazole and naproxen) is more effective in reducing the occurrence of gastroduodenal
      ulcers, dyspepsia, and heartburn in subjects at risk for developing NSAID-associated gastric
      ulcers compared to naproxen alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives:

      Primary: To demonstrate that PN400 is effective in reducing the risk of gastric ulcers in
      subjects at risk for developing NSAID-associated gastric ulcers.

      Secondary:

        -  To determine if PN400 is effective in reducing the risk of duodenal ulcers in subjects
           at risk for developing NSAID-associated ulcers

        -  To compare upper gastrointestinal symptoms in subjects treated with PN400 versus
           naproxen as measured by scores on the Severity of Dyspepsia Assessment (SODA) instrument
           and the Overall Treatment Evaluation - Dyspepsia (OTE-DP)

        -  To compare heartburn symptoms in subjects treated with PN400 versus naproxen

        -  To evaluate the safety and tolerability of PN400 and naproxen
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Gastric Ulcer Confirmed by Endoscopy</measure>
    <time_frame>6 months</time_frame>
    <description>The primary efficacy endpoint was the number of subjects with gastric ulcers at any time throughout 6 months of treatment. An ulcer was defined as a mucosal break of at least 3 mm in diameter (measured by close application of open endoscopic biopsy forceps) with unequivocal crater depth. A subject is considered to have completed the study if all scheduled assessments up through the 6 month visit have been performed or if the endpoint of gastric ulcer confirmed by endoscopy has been reached.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Number of Participants With Pre-Specified NSAID-Associated Upper GI Adverse Events or Duodenal Ulcers</measure>
    <time_frame>6 months</time_frame>
    <description>The Number of Participants with Pre-Specified non-steroidal antiinflammatory drug (NSAID)-Associated Upper Gastrointestinal (UGI) Adverse Events or Duodenal Ulcers after 6 months of treatment. Pre-specified UGI adverse events typically associated with NSAID use include dyspepsia, abdominal pain, gastritis, erosive esophagitis, duodenitis, abdominal discomfort</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Participants Discontinuing From the Study Due to NSAID-Associated Upper GI Adverse Events or to Duodenal Ulcer</measure>
    <time_frame>6 Months</time_frame>
    <description>The Number of Participants Discontinuing from the Study Due to non-steroidal antiinflammatory drug (NSAID)-Associated Upper GI Adverse Events or to Duodenal Ulcer during the treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Participants Developing Duodenal Ulcers Throughout 6 Months of Treatment</measure>
    <time_frame>6 months</time_frame>
    <description>The Number of Participants Developing Duodenal Ulcers at any time during the 6 Months of the treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heartburn Symptom Resolution, ie no Heartburn Symptoms During the Last 7 Days Prior to the Visit</measure>
    <time_frame>6 months</time_frame>
    <description>Subjects were asked whether heartburn symptoms within the 7 days prior to the visit were:
none: no symptoms
mild: awareness of symptom, but easily tolerated
moderate: discomforting symptom sufficient to cause interference with normal activities (including sleep)
severe: incapacitating symptom, with inability to perform normal activities (including sleep) Heartburn was defined as a burning feeling rising from the stomach or lower part of the chest towards the neck.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement From Baseline in Upper Abdominal Pain and Discomfort Scores at 6 Months, Based on the Overall Treatment Evaluation for Dyspepsia Questionnaire</measure>
    <time_frame>change from baseline at 6 Months</time_frame>
    <description>Improvement from baseline in Upper Abdominal Pain and Discomfort scores at 6 months, based on the overall Treatment Evaluation for Dyspepsia Questionnaire. Subjects were asked: &quot;since treatment started, has there been any change in your upper abdominal pain and/or discomfort?&quot; Answers would be better/about the same/worse. Participants with the response &quot;better&quot; (instead of &quot;about the same&quot; or &quot;worse&quot;), are tabulated by treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline on Pain Intensity of the Severity of Dyspepsia Assessment (SODA) Subscales</measure>
    <time_frame>Baseline to 6 Months</time_frame>
    <description>Mean Change from Baseline on Pain Intensity of the Severity of Dyspepsia Assessment (SODA) Subscales. There are 6 questions about abdominal pain during the past 7 days: q 1-5 on average: 1. rate with a number between 0 (no pain) and 100 (pain as bad as it could be), 2. rate with a number between 0 (no discomfort) and 10 (discomfort as bad as it can be), 3. on a scale of 5 (from none to excriciating), 4. on 100 mm VAS, 5. on a scale of 4 and 6. worst abdominal pain scale 0 (no discomfort) and 10 (discomfort as bad as it can be). Total composite possible range for &quot;pain intensity&quot; is: 2-47</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline on Non-Pain Symptoms of the Severity of Dyspepsia Assessment (SODA) Subscales</measure>
    <time_frame>baseline to 6 Months</time_frame>
    <description>Change from Baseline of Non-Pain Symptoms on the SODA Assessment. There are 7 categories about the non-pain symptoms: burping/beching, heartburn, bloating, passing gas, sour taste, nausea and bad breath. For each of these categories, subjects were to rate during the past seven days, on average, the severity on a 5 point scale ranging from no problem to very severe problem. The scores are combined into a single composite score. The total possible range of the non-pain symptoms subscale is: 7-35.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline on Satisfaction of the Severity of Dyspepsia Assessment (SODA) Subscales</measure>
    <time_frame>baseline to 6 Months</time_frame>
    <description>Mean Change in Satisfaction on SODA Assessment. Questions/statements to rate about satisfaction/dissatisfaction with their present level of abdominal discomfort. Question 1: 4-point scale range 0 (extremely unhappy) to 4 (extremely happy), statement 2 (I feel satisfied with my health with regard to abdominal discomfort) &amp; statement 3 (I am pleased because my abdominal discomfort seems under control) on a 5 point scale (definitely true to definitely false) &amp; question 4 rated how pleased subjects were with abdominal discomfort on a 10 point scale. Total satisfaction composite range: 2-23</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">420</enrollment>
  <condition>Gastric Ulcer</condition>
  <arm_group>
    <arm_group_label>PN400</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Naproxen 500 mg/Immediate-Release Esomeprazole 20 mg dosed twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Naproxen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Naproxen 500 mg dosed twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PN400 (VIMOVO)</intervention_name>
    <description>PN400 tablets (Naproxen 500 mg and Esomeprazole 20 mg) twice daily (bid) taken orally.</description>
    <arm_group_label>PN400</arm_group_label>
    <other_name>Vimovo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naproxen</intervention_name>
    <description>Naproxen 500 mg dosed twice daily (bid) orally</description>
    <arm_group_label>Naproxen</arm_group_label>
    <other_name>Naprosyn</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        A subject was eligible for inclusion in this study if all of the following criteria
        applied:

          1. Male or non-pregnant, non-breastfeeding female subjects with a history of
             osteoarthritis, rheumatoid arthritis, ankylosing spondylitis or other medical
             conditions expected to require daily NSAID therapy for at least 6 months, who were

               -  18-49 years of age and had a history of a documented, uncomplicated gastric or
                  duodenal ulcer (a mucosal break of at least 3 mm in diameter with depth, without
                  any concurrent bleeding, clot or perforation) within the past 5 years OR, who
                  were

               -  50 years of age and older (These subjects did not require a history of a
                  documented, uncomplicated gastric or duodenal ulcer within the past 5 years.)

          2. Female subjects were eligible for participation in the study if they were of

               -  non-childbearing potential (i.e., physiologically incapable of becoming
                  pregnant);

               -  childbearing potential, had a negative pregnancy test at Screening, and at least
                  1 of the following applied or was agreed to by the subject:

               -  Female sterilization or sterilization of male partner

               -  Hormonal contraception by oral route, implant, injectable, vaginal ring

               -  Any intrauterine device with published data showing that the lowest expected
                  failure rate is &lt; 1% per year

               -  Double barrier method (2 physical barriers or 1 physical barrier plus spermicide)

               -  Any other method with published data showing that the lowest expected failure
                  rate is &lt; 1% per year

          3. Each subject was required to understand and comply with study procedures required of a
             subject and was able and willing to provide written informed consent prior to any
             study procedures being performed.

        Exclusion Criteria

        A subject was not eligible for this study if any 1 or more of the following criteria
        applied:

          1. History of hypersensitivity to esomeprazole or to another PPI

          2. History of allergic reaction or intolerance to any NSAID (including aspirin) and/or a
             history of NSAID-induced symptoms of asthma, rhinitis, and/or nasal polyps

          3. Participation in any study of an investigational treatment in the 4 weeks before
             Screening

          4. Presence of uncontrolled acute or chronic medical illness, e.g., GI disorder,
             hypertension, diabetes, thyroid disorder, depression and/or infection that would have
             endangered a subject if they were to have participated in the study

          5. GI disorder or surgery leading to impaired drug absorption

          6. Evidence of uncontrolled, or unstable cardio- or cerebrovascular disorder, which in
             the investigator's opinion would have endangered a subject if they were to have
             participated in the study

          7. Schizophrenia or bipolar disorder

          8. Use of any excluded concomitant medication (see Section 9.4.8)

          9. A recent history (in the past 3 months) suggestive of alcohol or drug abuse or
             dependence, including overuse/abuse of narcotics for management of pain

         10. Serious blood coagulation disorder, including use of systemic anticoagulants

         11. Positive test result for H. pylori at Screening

         12. Screening endoscopy showing any gastric or duodenal ulcer at least 3 mm in diameter
             with depth

         13. Screening laboratory alanine aminotransferase (ALT) or aspartate aminotransferase
             (AST) value &gt; 2 times the upper limit of normal

         14. Estimated creatinine clearance &lt; 30 ml/min

         15. Other than noted specifically, any screening laboratory value that was clinically
             significant in the investigator's opinion and would have endangered a subject if they
             were to have participated in the study

         16. History of malignancy, treated or untreated, within the past 5 years, with the
             exception of successfully treated basal cell or squamous cell carcinoma of the skin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Everardus Orlemans, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>POZEN</affiliation>
  </overall_official>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2010</study_first_submitted>
  <study_first_submitted_qc>May 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2010</study_first_posted>
  <results_first_submitted>May 27, 2010</results_first_submitted>
  <results_first_submitted_qc>November 29, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 28, 2010</results_first_posted>
  <last_update_submitted>November 29, 2010</last_update_submitted>
  <last_update_submitted_qc>November 29, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 28, 2010</last_update_posted>
  <responsible_party>
    <name_title>Senior Vice President, Clinical Research</name_title>
    <organization>Pozen, Inc</organization>
  </responsible_party>
  <keyword>NSAID</keyword>
  <keyword>gastric ulcers</keyword>
  <keyword>Vimovo</keyword>
  <keyword>Esomeprazole</keyword>
  <keyword>Naproxen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Stomach Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esomeprazole</mesh_term>
    <mesh_term>Naproxen</mesh_term>
    <mesh_term>Anti-Inflammatory Agents, Non-Steroidal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A multi-center US study in which 70 sites recruited subjects between September 2007 and September 2008</recruitment_details>
      <pre_assignment_details>Screening for eligibility and wash-out of restricted medications</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>PN400 (VIMOVO)</title>
          <description>Naproxen 500 mg/Immediate-Release Esomeprazole 20 mg dosed twice daily (bid)</description>
        </group>
        <group group_id="P2">
          <title>Naproxen</title>
          <description>Naproxen 500 mg dosed twice daily (bid)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="210">Safety, Intent-to-Treat population</participants>
                <participants group_id="P2" count="210">Safety, Intent-to-Treat population</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="151"/>
                <participants group_id="P2" count="153"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
                <participants group_id="P2" count="57"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Duodenal Ulcer</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>misc</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PN400 (VIMOVO)</title>
          <description>Naproxen 500 mg/Immediate-Release Esomeprazole 20 mg dosed twice daily (bid)</description>
        </group>
        <group group_id="B2">
          <title>Naproxen</title>
          <description>Naproxen 500 mg dosed twice daily (bid)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="210"/>
            <count group_id="B2" value="210"/>
            <count group_id="B3" value="420"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.6" spread="8.2"/>
                    <measurement group_id="B2" value="59.4" spread="8.3"/>
                    <measurement group_id="B3" value="59.5" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="132"/>
                    <measurement group_id="B2" value="142"/>
                    <measurement group_id="B3" value="274"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Gastric Ulcer Confirmed by Endoscopy</title>
        <description>The primary efficacy endpoint was the number of subjects with gastric ulcers at any time throughout 6 months of treatment. An ulcer was defined as a mucosal break of at least 3 mm in diameter (measured by close application of open endoscopic biopsy forceps) with unequivocal crater depth. A subject is considered to have completed the study if all scheduled assessments up through the 6 month visit have been performed or if the endpoint of gastric ulcer confirmed by endoscopy has been reached.</description>
        <time_frame>6 months</time_frame>
        <population>Intent to Treat (ITT) Population</population>
        <group_list>
          <group group_id="O1">
            <title>PN400 (VIMOVO)</title>
            <description>Naproxen 500 mg/Immediate-Release Esomeprazole 20 mg dosed twice daily (bid)</description>
          </group>
          <group group_id="O2">
            <title>Naproxen</title>
            <description>Naproxen 500 mg dosed twice daily (bid)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Gastric Ulcer Confirmed by Endoscopy</title>
          <description>The primary efficacy endpoint was the number of subjects with gastric ulcers at any time throughout 6 months of treatment. An ulcer was defined as a mucosal break of at least 3 mm in diameter (measured by close application of open endoscopic biopsy forceps) with unequivocal crater depth. A subject is considered to have completed the study if all scheduled assessments up through the 6 month visit have been performed or if the endpoint of gastric ulcer confirmed by endoscopy has been reached.</description>
          <population>Intent to Treat (ITT) Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="210"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" lower_limit="4.1" upper_limit="11.5"/>
                    <measurement group_id="O2" value="51" lower_limit="18.6" upper_limit="30.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The primary efficacy endpoint was the proportion of subjetcs developing gastric ulcers throughout 6 months of study treatment. A summary, including cumulative frequency and percentage with associated 95% confidence intervals was produced for the observational incidences of gastric ulcers at 6 months. The cumulative proportion of subjects developing gastric ulcers at 6 months was analyzed using the CMH test stratified by use of low-dose aspirin (Yes/No) at randomization.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>CMH test stratified by use of low-dose aspirin (Yes/No) at randomization.</method_desc>
            <param_type>proportions</param_type>
            <param_value>11.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.9</ci_lower_limit>
            <ci_upper_limit>17.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Participants With Pre-Specified NSAID-Associated Upper GI Adverse Events or Duodenal Ulcers</title>
        <description>The Number of Participants with Pre-Specified non-steroidal antiinflammatory drug (NSAID)-Associated Upper Gastrointestinal (UGI) Adverse Events or Duodenal Ulcers after 6 months of treatment. Pre-specified UGI adverse events typically associated with NSAID use include dyspepsia, abdominal pain, gastritis, erosive esophagitis, duodenitis, abdominal discomfort</description>
        <time_frame>6 months</time_frame>
        <population>Intent to Treat (ITT) Population</population>
        <group_list>
          <group group_id="O1">
            <title>PN400 (VIMOVO)</title>
            <description>Naproxen 500 mg/Immediate-Release Esomeprazole 20 mg dosed twice daily (bid)</description>
          </group>
          <group group_id="O2">
            <title>Naproxen</title>
            <description>Naproxen 500 mg dosed twice daily (bid)</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Participants With Pre-Specified NSAID-Associated Upper GI Adverse Events or Duodenal Ulcers</title>
          <description>The Number of Participants with Pre-Specified non-steroidal antiinflammatory drug (NSAID)-Associated Upper Gastrointestinal (UGI) Adverse Events or Duodenal Ulcers after 6 months of treatment. Pre-specified UGI adverse events typically associated with NSAID use include dyspepsia, abdominal pain, gastritis, erosive esophagitis, duodenitis, abdominal discomfort</description>
          <population>Intent to Treat (ITT) Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="210"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114" lower_limit="47.3" upper_limit="61.2"/>
                    <measurement group_id="O2" value="151" lower_limit="65.3" upper_limit="77.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Participants Discontinuing From the Study Due to NSAID-Associated Upper GI Adverse Events or to Duodenal Ulcer</title>
        <description>The Number of Participants Discontinuing from the Study Due to non-steroidal antiinflammatory drug (NSAID)-Associated Upper GI Adverse Events or to Duodenal Ulcer during the treatment period</description>
        <time_frame>6 Months</time_frame>
        <population>Intent to Treat (ITT) Population</population>
        <group_list>
          <group group_id="O1">
            <title>PN400 (VIMOVO)</title>
            <description>Naproxen 500 mg/Immediate-Release Esomeprazole 20 mg dosed twice daily (bid)</description>
          </group>
          <group group_id="O2">
            <title>Naproxen</title>
            <description>Naproxen 500 mg dosed twice daily (bid)</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Participants Discontinuing From the Study Due to NSAID-Associated Upper GI Adverse Events or to Duodenal Ulcer</title>
          <description>The Number of Participants Discontinuing from the Study Due to non-steroidal antiinflammatory drug (NSAID)-Associated Upper GI Adverse Events or to Duodenal Ulcer during the treatment period</description>
          <population>Intent to Treat (ITT) Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="210"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="2.3" upper_limit="8.6"/>
                    <measurement group_id="O2" value="25" lower_limit="7.9" upper_limit="17.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.009</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Participants Developing Duodenal Ulcers Throughout 6 Months of Treatment</title>
        <description>The Number of Participants Developing Duodenal Ulcers at any time during the 6 Months of the treatment period</description>
        <time_frame>6 months</time_frame>
        <population>Intent to treat (ITT) population</population>
        <group_list>
          <group group_id="O1">
            <title>PN400 (VIMOVO)</title>
            <description>Naproxen 500 mg/Immediate-Release Esomeprazole 20 mg dosed twice daily (bid)</description>
          </group>
          <group group_id="O2">
            <title>Naproxen</title>
            <description>Naproxen 500 mg dosed twice daily (bid)</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Participants Developing Duodenal Ulcers Throughout 6 Months of Treatment</title>
          <description>The Number of Participants Developing Duodenal Ulcers at any time during the 6 Months of the treatment period</description>
          <population>Intent to treat (ITT) population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="210"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="0.1" upper_limit="3.4"/>
                    <measurement group_id="O2" value="12" lower_limit="3.0" upper_limit="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.007</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Heartburn Symptom Resolution, ie no Heartburn Symptoms During the Last 7 Days Prior to the Visit</title>
        <description>Subjects were asked whether heartburn symptoms within the 7 days prior to the visit were:
none: no symptoms
mild: awareness of symptom, but easily tolerated
moderate: discomforting symptom sufficient to cause interference with normal activities (including sleep)
severe: incapacitating symptom, with inability to perform normal activities (including sleep) Heartburn was defined as a burning feeling rising from the stomach or lower part of the chest towards the neck.</description>
        <time_frame>6 months</time_frame>
        <population>Intent to Treat (ITT) Population</population>
        <group_list>
          <group group_id="O1">
            <title>PN400 (VIMOVO)</title>
            <description>Naproxen 500 mg/Immediate-Release Esomeprazole 20 mg dosed twice daily (bid)</description>
          </group>
          <group group_id="O2">
            <title>Naproxen</title>
            <description>Naproxen 500 mg dosed twice daily (bid)</description>
          </group>
        </group_list>
        <measure>
          <title>Heartburn Symptom Resolution, ie no Heartburn Symptoms During the Last 7 Days Prior to the Visit</title>
          <description>Subjects were asked whether heartburn symptoms within the 7 days prior to the visit were:
none: no symptoms
mild: awareness of symptom, but easily tolerated
moderate: discomforting symptom sufficient to cause interference with normal activities (including sleep)
severe: incapacitating symptom, with inability to perform normal activities (including sleep) Heartburn was defined as a burning feeling rising from the stomach or lower part of the chest towards the neck.</description>
          <population>Intent to Treat (ITT) Population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="210"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102"/>
                    <measurement group_id="O2" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Improvement From Baseline in Upper Abdominal Pain and Discomfort Scores at 6 Months, Based on the Overall Treatment Evaluation for Dyspepsia Questionnaire</title>
        <description>Improvement from baseline in Upper Abdominal Pain and Discomfort scores at 6 months, based on the overall Treatment Evaluation for Dyspepsia Questionnaire. Subjects were asked: &quot;since treatment started, has there been any change in your upper abdominal pain and/or discomfort?&quot; Answers would be better/about the same/worse. Participants with the response &quot;better&quot; (instead of &quot;about the same&quot; or &quot;worse&quot;), are tabulated by treatment group.</description>
        <time_frame>change from baseline at 6 Months</time_frame>
        <population>Intent to Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>PN400 (VIMOVO)</title>
            <description>Naproxen 500 mg/Immediate-Release Esomeprazole 20 mg dosed twice daily (bid)</description>
          </group>
          <group group_id="O2">
            <title>Naproxen</title>
            <description>Naproxen 500 mg dosed twice daily (bid)</description>
          </group>
        </group_list>
        <measure>
          <title>Improvement From Baseline in Upper Abdominal Pain and Discomfort Scores at 6 Months, Based on the Overall Treatment Evaluation for Dyspepsia Questionnaire</title>
          <description>Improvement from baseline in Upper Abdominal Pain and Discomfort scores at 6 months, based on the overall Treatment Evaluation for Dyspepsia Questionnaire. Subjects were asked: &quot;since treatment started, has there been any change in your upper abdominal pain and/or discomfort?&quot; Answers would be better/about the same/worse. Participants with the response &quot;better&quot; (instead of &quot;about the same&quot; or &quot;worse&quot;), are tabulated by treatment group.</description>
          <population>Intent to Treat Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="210"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79"/>
                    <measurement group_id="O2" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline on Pain Intensity of the Severity of Dyspepsia Assessment (SODA) Subscales</title>
        <description>Mean Change from Baseline on Pain Intensity of the Severity of Dyspepsia Assessment (SODA) Subscales. There are 6 questions about abdominal pain during the past 7 days: q 1-5 on average: 1. rate with a number between 0 (no pain) and 100 (pain as bad as it could be), 2. rate with a number between 0 (no discomfort) and 10 (discomfort as bad as it can be), 3. on a scale of 5 (from none to excriciating), 4. on 100 mm VAS, 5. on a scale of 4 and 6. worst abdominal pain scale 0 (no discomfort) and 10 (discomfort as bad as it can be). Total composite possible range for &quot;pain intensity&quot; is: 2-47</description>
        <time_frame>Baseline to 6 Months</time_frame>
        <population>Intent to Treat (ITT) Population</population>
        <group_list>
          <group group_id="O1">
            <title>PN400 (VIMOVO)</title>
            <description>Naproxen 500 mg/Immediate-Release Esomeprazole 20 mg dosed twice daily (bid)</description>
          </group>
          <group group_id="O2">
            <title>Naproxen</title>
            <description>Naproxen 500 mg dosed twice daily (bid)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline on Pain Intensity of the Severity of Dyspepsia Assessment (SODA) Subscales</title>
          <description>Mean Change from Baseline on Pain Intensity of the Severity of Dyspepsia Assessment (SODA) Subscales. There are 6 questions about abdominal pain during the past 7 days: q 1-5 on average: 1. rate with a number between 0 (no pain) and 100 (pain as bad as it could be), 2. rate with a number between 0 (no discomfort) and 10 (discomfort as bad as it can be), 3. on a scale of 5 (from none to excriciating), 4. on 100 mm VAS, 5. on a scale of 4 and 6. worst abdominal pain scale 0 (no discomfort) and 10 (discomfort as bad as it can be). Total composite possible range for &quot;pain intensity&quot; is: 2-47</description>
          <population>Intent to Treat (ITT) Population</population>
          <units>Units on SODA Subscale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="210"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3" spread="0.7"/>
                    <measurement group_id="O2" value="0" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline on Non-Pain Symptoms of the Severity of Dyspepsia Assessment (SODA) Subscales</title>
        <description>Change from Baseline of Non-Pain Symptoms on the SODA Assessment. There are 7 categories about the non-pain symptoms: burping/beching, heartburn, bloating, passing gas, sour taste, nausea and bad breath. For each of these categories, subjects were to rate during the past seven days, on average, the severity on a 5 point scale ranging from no problem to very severe problem. The scores are combined into a single composite score. The total possible range of the non-pain symptoms subscale is: 7-35.</description>
        <time_frame>baseline to 6 Months</time_frame>
        <population>Intent to Treat (ITT) Population</population>
        <group_list>
          <group group_id="O1">
            <title>PN400 (VIMOVO)</title>
            <description>Naproxen 500 mg/Immediate-Release Esomeprazole 20 mg dosed twice daily (bid)</description>
          </group>
          <group group_id="O2">
            <title>Naproxen</title>
            <description>Naproxen 500 mg dosed twice daily (bid)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline on Non-Pain Symptoms of the Severity of Dyspepsia Assessment (SODA) Subscales</title>
          <description>Change from Baseline of Non-Pain Symptoms on the SODA Assessment. There are 7 categories about the non-pain symptoms: burping/beching, heartburn, bloating, passing gas, sour taste, nausea and bad breath. For each of these categories, subjects were to rate during the past seven days, on average, the severity on a 5 point scale ranging from no problem to very severe problem. The scores are combined into a single composite score. The total possible range of the non-pain symptoms subscale is: 7-35.</description>
          <population>Intent to Treat (ITT) Population</population>
          <units>Units on SODA Subscale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="210"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="0.3"/>
                    <measurement group_id="O2" value="0.1" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline on Satisfaction of the Severity of Dyspepsia Assessment (SODA) Subscales</title>
        <description>Mean Change in Satisfaction on SODA Assessment. Questions/statements to rate about satisfaction/dissatisfaction with their present level of abdominal discomfort. Question 1: 4-point scale range 0 (extremely unhappy) to 4 (extremely happy), statement 2 (I feel satisfied with my health with regard to abdominal discomfort) &amp; statement 3 (I am pleased because my abdominal discomfort seems under control) on a 5 point scale (definitely true to definitely false) &amp; question 4 rated how pleased subjects were with abdominal discomfort on a 10 point scale. Total satisfaction composite range: 2-23</description>
        <time_frame>baseline to 6 Months</time_frame>
        <population>Intent to Treat (ITT) Population</population>
        <group_list>
          <group group_id="O1">
            <title>PN400 (VIMOVO)</title>
            <description>Naproxen 500 mg/Immediate-Release Esomeprazole 20 mg dosed twice daily (bid)</description>
          </group>
          <group group_id="O2">
            <title>Naproxen</title>
            <description>Naproxen 500 mg dosed twice daily (bid)</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline on Satisfaction of the Severity of Dyspepsia Assessment (SODA) Subscales</title>
          <description>Mean Change in Satisfaction on SODA Assessment. Questions/statements to rate about satisfaction/dissatisfaction with their present level of abdominal discomfort. Question 1: 4-point scale range 0 (extremely unhappy) to 4 (extremely happy), statement 2 (I feel satisfied with my health with regard to abdominal discomfort) &amp; statement 3 (I am pleased because my abdominal discomfort seems under control) on a 5 point scale (definitely true to definitely false) &amp; question 4 rated how pleased subjects were with abdominal discomfort on a 10 point scale. Total satisfaction composite range: 2-23</description>
          <population>Intent to Treat (ITT) Population</population>
          <units>Units on SODA Subscale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="210"/>
                <count group_id="O2" value="210"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="0.4"/>
                    <measurement group_id="O2" value="0.5" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Randomization through 6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>PN400 (VIMOVO)</title>
          <description>Naproxen 500 mg/Immediate-Release Esomeprazole 20 mg dosed twice daily (bid)</description>
        </group>
        <group group_id="E2">
          <title>Naproxen</title>
          <description>Naproxen 500 mg dosed twice daily (bid)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (10.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Post-procedural hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Mastectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (10.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="160" subjects_at_risk="210"/>
                <counts group_id="E2" subjects_affected="174" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="41" subjects_affected="41" subjects_at_risk="210"/>
                <counts group_id="E2" events="49" subjects_affected="49" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" events="38" subjects_affected="38" subjects_at_risk="210"/>
                <counts group_id="E2" events="81" subjects_affected="81" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="34" subjects_affected="34" subjects_at_risk="210"/>
                <counts group_id="E2" events="32" subjects_affected="32" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="210"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="210"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="210"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="210"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="210"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="210"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="210"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="210"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="210"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Erosive duodenitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="210"/>
                <counts group_id="E2" events="20" subjects_affected="20" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="210"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="210"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Duodenitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="210"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Erosive oesophagitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="210"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Gastritis haemorrhagic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="210"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="210"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="210"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="210"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="210"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="210"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="210"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="210"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="210"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="210"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>PI agrees that the first publication will be a multi-center publication of the study results. Following this multi-center publication, PI can publish, present or use any non-confidential study results following Sponsor review and comment.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Clinical Research</name_or_title>
      <organization>POZEN</organization>
      <phone>919-913-1030</phone>
      <email>eorlemans@pozen.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

